Relay Therapeutics (RLAY) Other Non Operating Income (2019 - 2026)

Relay Therapeutics (RLAY) has 8 years of Other Non Operating Income data on file, last reported at $5.3 million in Q1 2026.

• Quarterly Other Non Operating Income fell 32.1% year-over-year to $5.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $23.8 million (down 29.28% YoY) and the FY2025 annual result came in at $26.3 million, down 24.46% from the prior year.
• Other Non Operating Income retreated to $5.3 million in Q1 2026 per RLAY's latest filing, from $5.7 million in the prior quarter.
• Across five years, Other Non Operating Income topped out at $9.0 million in Q1 2024 and bottomed at $675000.0 in Q1 2022.
• The 5-year median for Other Non Operating Income is $6.9 million (2023), against an average of $6.2 million.
• The widest annual swing landed in 2022, when Other Non Operating Income surged 1903.0%; it then plunged 36.04% in 2025.
• Tracing RLAY's Other Non Operating Income over 5 years: stood at $5.3 million in 2022, then surged by 62.7% to $8.7 million in 2023, then grew by 3.15% to $9.0 million in 2024, then tumbled by 36.04% to $5.7 million in 2025, then fell by 7.68% to $5.3 million in 2026.
• Per Business Quant, the three latest RLAY Other Non Operating Income figures stand at $5.3 million (Q1 2026), $5.7 million (Q4 2025), and $6.2 million (Q3 2025).

Peer Comparison